Longboard Pharmaceuticals, Inc. (LBPH)

21.38 -1.43 (-6.29%) 收市：04:00PM EDT

Longboard Pharmaceuticals, Inc.

4275 Executive Square
Suite 950
La Jolla, CA 92037
United States
858-789-9283
https://www.longboardpharma.com

版塊: Healthcare
行業: Biotechnology
全職員工: 50

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Kevin R. Lind	President, CEO, Secretary & Director	1.07M	無	1976
Ms. Brandi L. Roberts CPA, M.B.A.	Executive VP & CFO	662.65k	無	1974
Dr. Randall E. Kaye M.D.	Executive VP & Chief Medical Officer	717.95k	無	1962
Mr. Chadwick J. Orevillo MPH	Executive VP & Head of Operations	無	無	無
Megan E. Knight	VP & Head of Investor Relations	無	無	無
Mr. Steven W. Spector J.D.	Executive VP, Head of Business Development & General Counsel	無	無	1965
Dr. Anne M. Danks Ph.D.	VP & Head of Nonclinical Research & Development	無	無	無
Mr. Gus Cardenas	VP & Head of Quality Assurance	無	無	無
Dr. Marco Peters Ph.D.	VP & Head of Translational Science	無	無	無
Dr. Dewey McLin Ph.D.	VP & Head of Medical Affairs	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

公司管治

截至 2024年5月1日 止，Longboard Pharmaceuticals, Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：8；董事會：8；股東權利：8；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。